Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study.

Date publication

avril 2022

Journal

Advances in therapy

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LEPAGE Côme

Tous les auteurs :
Smith D, Lepage C, Vicaut E, Dominguez S, Coriat R, Dubreuil O, Lecomte T, Baudin E, Venat Bouvet L, Samalin E, Santos A, Borie O, Bisot-Locard S, Goichot B, Lombard-Bohas C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35419649

Résumé

Approval of sunitinib and everolimus for the treatment of progressive, unresectable or metastatic well-differentiated pancreatic neuroendocrine tumors (pNETs) was obtained in France in 2011 and 2012, respectively. OPALINE was set up as an observational study to evaluate the efficacy of sunitinib and everolimus compared to usual pNET treatments of chemotherapies and somatostatin analogues that had been previously recommended by the health authorities.

Mots clés

2-Year morbi-mortality, Ambispective study, Everolimus, Pancreatic neuroendocrine tumor, Sunitinib, pNET

Référence

Adv Ther. 2022 Apr 13;: